Overview

MT2004-30: Tomotherapy for Solid Tumors

Status:
Terminated
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Busulfan
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Lenograstim
Melphalan
Mesna
Sargramostim
Thiotepa